FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GTF2IRD1-ALK

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GTF2IRD1-ALK
FusionPDB ID: 35245
FusionGDB2.0 ID: 35245
HgeneTgene
Gene symbol

GTF2IRD1

ALK

Gene ID

9569

238

Gene nameGTF2I repeat domain containing 1ALK receptor tyrosine kinase
SynonymsBEN|CREAM1|GTF3|MUSTRD1|RBAP2|WBS|WBSCR11|WBSCR12|hMusTRD1alpha1CD246|NBLST3
Cytomap

7q11.23

2p23.2-p23.1

Type of geneprotein-codingprotein-coding
Descriptiongeneral transcription factor II-I repeat domain-containing protein 1USE B1-binding proteinWilliams-Beuren syndrome chromosome region 11binding factor for early enhancergeneral transcription factor 3general transcription factor IIImuscle TFII-I repeaALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase
Modification date2020031320200329
UniProtAcc

Q9UHL9

Main function of 5'-partner protein: FUNCTION: May be a transcription regulator involved in cell-cycle progression and skeletal muscle differentiation. May repress GTF2I transcriptional functions, by preventing its nuclear residency, or by inhibiting its transcriptional activation. May contribute to slow-twitch fiber type specificity during myogenesis and in regenerating muscles. Binds troponin I slow-muscle fiber enhancer (USE B1). Binds specifically and with high affinity to the EFG sequences derived from the early enhancer of HOXC8 (By similarity). {ECO:0000250, ECO:0000269|PubMed:11438732}.

Q96BT7

Main function of 5'-partner protein: FUNCTION: Catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its methyltransferase domain (PubMed:20123966, PubMed:20308323, PubMed:31079898). Catalyzes the last step in the formation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA (PubMed:20123966, PubMed:20308323). Has a preference for tRNA(Arg) and tRNA(Glu), and does not bind tRNA(Lys)(PubMed:20308323). Binds tRNA and catalyzes the iron and alpha-ketoglutarate dependent hydroxylation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its dioxygenase domain, giving rise to 5-(S)-methoxycarbonylhydroxymethyluridine; has a preference for tRNA(Gly) (PubMed:21285950). Required for normal survival after DNA damage (PubMed:20308323). May inhibit apoptosis and promote cell survival and angiogenesis (PubMed:19293182). {ECO:0000269|PubMed:19293182, ECO:0000269|PubMed:20123966, ECO:0000269|PubMed:20308323, ECO:0000269|PubMed:21285950, ECO:0000269|PubMed:31079898}.
Ensembl transtripts involved in fusion geneENST idsENST00000489094, ENST00000265755, 
ENST00000424337, ENST00000455841, 
ENST00000476977, 
ENST00000389048, 
ENST00000431873, ENST00000498037, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score11 X 6 X 9=59456 X 74 X 20=82880
# samples 1257
** MAII scorelog2(12/594*10)=-2.30742852519225
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(57/82880*10)=-7.18391827352181
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GTF2IRD1 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GTF2IRD1 [Title/Abstract] AND ALK [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GTF2IRD1(73935627)-ALK(29446394), # samples:3
Anticipated loss of major functional domain due to fusion event.GTF2IRD1-ALK seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GTF2IRD1-ALK seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GTF2IRD1-ALK seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
GTF2IRD1-ALK seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneALK

GO:0016310

phosphorylation

9174053

TgeneALK

GO:0046777

protein autophosphorylation

9174053



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:73935627/chr2:29446394)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GTF2IRD1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ALK (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000265755GTF2IRD1chr773935627+ENST00000389048ALKchr229446394-354013993303089919
ENST00000455841GTF2IRD1chr773935627+ENST00000389048ALKchr229446394-345613151503005951
ENST00000424337GTF2IRD1chr773935627+ENST00000389048ALKchr229446394-32211080112770919
ENST00000476977GTF2IRD1chr773935627+ENST00000389048ALKchr229446394-4838269716914387898

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000265755ENST00000389048GTF2IRD1chr773935627+ALKchr229446394-0.0053528640.9946471
ENST00000455841ENST00000389048GTF2IRD1chr773935627+ALKchr229446394-0.0043992820.9956007
ENST00000424337ENST00000389048GTF2IRD1chr773935627+ALKchr229446394-0.0053839780.994616
ENST00000476977ENST00000389048GTF2IRD1chr773935627+ALKchr229446394-0.011810.98819005

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GTF2IRD1-ALK

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GTF2IRD1chr773935627ALKchr2294463941080356SKRILFSIVHDKSVYRRKHQELQAMQ
GTF2IRD1chr773935627ALKchr2294463941315388SKRILFSIVHDKSVYRRKHQELQAMQ
GTF2IRD1chr773935627ALKchr2294463941399356SKRILFSIVHDKSVYRRKHQELQAMQ
GTF2IRD1chr773935627ALKchr2294463942697335SKRILFSIVHDKSVYRRKHQELQAMQ

Top

Potential FusionNeoAntigen Information of GTF2IRD1-ALK in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GTF2IRD1-ALK_73935627_29446394.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:01SIVHDKSVY0.99710.5993615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:25SIVHDKSVY0.99180.6148615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:02SIVHDKSVY0.98610.627615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:03IVHDKSVYR0.93420.5096716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:11IVHDKSVYR0.93420.5096716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:09IVHDKSVYR0.93420.5096716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A30:08IVHDKSVYR0.90830.5778716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A31:02IVHDKSVYR0.8430.5122716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B08:01SVYRRKHQEL0.9920.58451222
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A31:02IVHDKSVYRR0.92480.6349717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:03IVHDKSVYRR0.91780.6281717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:09IVHDKSVYRR0.91780.6281717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:11IVHDKSVYRR0.91780.6281717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A31:06IVHDKSVYRR0.82680.5278717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A03:12IVHDKSVYRRK0.94670.5536718
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A03:25IVHDKSVYRRK0.94440.524718
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:07FSIVHDKSV0.9980.886514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C15:06FSIVHDKSV0.99790.7215514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:19FSIVHDKSV0.98790.8955514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:21SIVHDKSVY0.98560.5551615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C06:03FSIVHDKSV0.98360.9586514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C12:04FSIVHDKSV0.98270.9675514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C12:12FSIVHDKSV0.9820.7941514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:08FSIVHDKSV0.97720.6965514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C02:06FSIVHDKSV0.55060.8781514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A31:01IVHDKSVYRR0.94940.6105717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A03:01IVHDKSVYRRK0.94440.524718
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C15:02FSIVHDKSV0.99840.7042514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C15:05FSIVHDKSV0.99840.7492514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:27SIVHDKSVY0.99710.6008615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:125SIVHDKSVY0.99710.5993615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:34SIVHDKSVY0.99710.5993615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:33SIVHDKSVY0.99710.5993615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:17FSIVHDKSV0.99690.809514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:135SIVHDKSVY0.99680.6212615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:05FSIVHDKSV0.99650.767514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:50SIVHDKSVY0.99420.5866615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:11SIVHDKSVY0.99410.5155615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:08SIVHDKSVY0.99270.5263615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B35:43SIVHDKSVY0.99130.5233615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C16:04FSIVHDKSV0.99080.8969514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:35SIVHDKSVY0.98670.547615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:06FSIVHDKSV0.9850.879514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C12:03FSIVHDKSV0.97890.9027514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:12SIVHDKSVY0.97410.536615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:03FSIVHDKSV0.94860.9087514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:04FSIVHDKSV0.94860.9087514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B15:20SIVHDKSVY0.93820.574615
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:01IVHDKSVYR0.93420.5096716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A30:01IVHDKSVYR0.92170.7212716
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C16:02FSIVHDKSV0.90980.9674514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C16:01FSIVHDKSV0.83210.9351514
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C03:02FSIVHDKSVY0.99690.7483515
GTF2IRD1-ALKchr773935627chr2294463941399HLA-B08:18SVYRRKHQEL0.9920.58451222
GTF2IRD1-ALKchr773935627chr2294463941399HLA-C16:04FSIVHDKSVY0.97820.8664515
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A74:01IVHDKSVYRR0.91780.6281717
GTF2IRD1-ALKchr773935627chr2294463941399HLA-A30:01IVHDKSVYRRK0.98180.8724718

Top

Potential FusionNeoAntigen Information of GTF2IRD1-ALK in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GTF2IRD1-ALK_73935627_29446394.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0301LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0301ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0301FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0301RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0303LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0303ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0303FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0303RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0305LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0305ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0305FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0307LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0307ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0307FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0307RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0310LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0310ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0310FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0310RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0313LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0313ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0313FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0313RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0315LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0315ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0315FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0315RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0318LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0318ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0318FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0318RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0320LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0320ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0320FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0320RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0322LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0322ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0322FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0322RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0324LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0324ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0324FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0326LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0326ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0326FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0326RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0328LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0328ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0328FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0328RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0330LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0330ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0330FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0330RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0332LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0332ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0332FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0332RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0334LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0334ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0334FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0334RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0336LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0336ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0336FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0336RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0338LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0338ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0340LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0340ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0340FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0342LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0342ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0342FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0342RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0344LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0344ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0344FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0344RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0346LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0346ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0346FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0346RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0348LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0348ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0348FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0348RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0350LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0350ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0350FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0350RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0352LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0352ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0352FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0352RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0354LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0354ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0354FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0354RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0802KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0809KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0815KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0821KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-0830KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1107LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1107ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1107FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1107RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1403KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1419LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1427KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1427DKSVYRRKHQELQAM1025
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1429LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1440KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1447LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1447ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1467KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1476LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1476ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1476FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1476RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1477KSVYRRKHQELQAMQ1126
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1479LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1479ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1479FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1479RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1525LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1525ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1525FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1525RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1601RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1603RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1604RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1605RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1607RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1608RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB1-1609RILFSIVHDKSVYRR217
GTF2IRD1-ALKchr773935627chr2294463941399DRB3-0204LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0106LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0106ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0106FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0111LFSIVHDKSVYRRKH419
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0111ILFSIVHDKSVYRRK318
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0111FSIVHDKSVYRRKHQ520
GTF2IRD1-ALKchr773935627chr2294463941399DRB5-0205LFSIVHDKSVYRRKH419

Top

Fusion breakpoint peptide structures of GTF2IRD1-ALK

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8676SIVHDKSVYRRKHQGTF2IRD1ALKchr773935627chr2294463941399

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GTF2IRD1-ALK

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8676SIVHDKSVYRRKHQ-7.9962-8.1096
HLA-B14:023BVN8676SIVHDKSVYRRKHQ-5.70842-6.74372
HLA-B52:013W398676SIVHDKSVYRRKHQ-6.83737-6.95077
HLA-B52:013W398676SIVHDKSVYRRKHQ-4.4836-5.5189
HLA-A11:014UQ28676SIVHDKSVYRRKHQ-10.0067-10.1201
HLA-A11:014UQ28676SIVHDKSVYRRKHQ-9.03915-10.0745
HLA-A24:025HGA8676SIVHDKSVYRRKHQ-6.56204-6.67544
HLA-A24:025HGA8676SIVHDKSVYRRKHQ-5.42271-6.45801
HLA-B44:053DX88676SIVHDKSVYRRKHQ-7.85648-8.89178
HLA-B44:053DX88676SIVHDKSVYRRKHQ-5.3978-5.5112
HLA-A02:016TDR8676SIVHDKSVYRRKHQ-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of GTF2IRD1-ALK

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GTF2IRD1-ALKchr773935627chr2294463941222SVYRRKHQELCAGTGTACCGCCGGAAGCACCAGGAGCTGC
GTF2IRD1-ALKchr773935627chr229446394514FSIVHDKSVTCTCCATCGTCCATGACAAGTCAGTGT
GTF2IRD1-ALKchr773935627chr229446394515FSIVHDKSVYTCTCCATCGTCCATGACAAGTCAGTGTACC
GTF2IRD1-ALKchr773935627chr229446394615SIVHDKSVYCCATCGTCCATGACAAGTCAGTGTACC
GTF2IRD1-ALKchr773935627chr229446394716IVHDKSVYRTCGTCCATGACAAGTCAGTGTACCGCC
GTF2IRD1-ALKchr773935627chr229446394717IVHDKSVYRRTCGTCCATGACAAGTCAGTGTACCGCCGGA
GTF2IRD1-ALKchr773935627chr229446394718IVHDKSVYRRKTCGTCCATGACAAGTCAGTGTACCGCCGGAAGC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GTF2IRD1-ALKchr773935627chr2294463941025DKSVYRRKHQELQAMACAAGTCAGTGTACCGCCGGAAGCACCAGGAGCTGCAAGCCATGC
GTF2IRD1-ALKchr773935627chr2294463941126KSVYRRKHQELQAMQAGTCAGTGTACCGCCGGAAGCACCAGGAGCTGCAAGCCATGCAGA
GTF2IRD1-ALKchr773935627chr229446394217RILFSIVHDKSVYRRGCATTCTCTTCTCCATCGTCCATGACAAGTCAGTGTACCGCCGGA
GTF2IRD1-ALKchr773935627chr229446394318ILFSIVHDKSVYRRKTTCTCTTCTCCATCGTCCATGACAAGTCAGTGTACCGCCGGAAGC
GTF2IRD1-ALKchr773935627chr229446394419LFSIVHDKSVYRRKHTCTTCTCCATCGTCCATGACAAGTCAGTGTACCGCCGGAAGCACC
GTF2IRD1-ALKchr773935627chr229446394520FSIVHDKSVYRRKHQTCTCCATCGTCCATGACAAGTCAGTGTACCGCCGGAAGCACCAGG

Top

Information of the samples that have these potential fusion neoantigens of GTF2IRD1-ALK

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
THCAGTF2IRD1-ALKchr773935627ENST00000265755chr229446394ENST00000389048TCGA-EL-A4KD-01A

Top

Potential target of CAR-T therapy development for GTF2IRD1-ALK

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to GTF2IRD1-ALK

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GTF2IRD1-ALK

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneALKC0007131Non-Small Cell Lung Carcinoma28CGI;CTD_human
TgeneALKC0027819Neuroblastoma13CGI;CTD_human;ORPHANET
TgeneALKC0152013Adenocarcinoma of lung (disorder)8CGI;CTD_human
TgeneALKC2751681NEUROBLASTOMA, SUSCEPTIBILITY TO, 38CLINGEN;UNIPROT
TgeneALKC0206180Ki-1+ Anaplastic Large Cell Lymphoma6CGI;CTD_human
TgeneALKC0334121Inflammatory Myofibroblastic Tumor4CGI;CTD_human;ORPHANET
TgeneALKC0018199Granuloma, Plasma Cell3CTD_human
TgeneALKC0007621Neoplastic Cell Transformation2CTD_human
TgeneALKC0027627Neoplasm Metastasis2CTD_human
TgeneALKC0238463Papillary thyroid carcinoma2ORPHANET
TgeneALKC0001973Alcoholic Intoxication, Chronic1PSYGENET
TgeneALKC0006118Brain Neoplasms1CGI;CTD_human
TgeneALKC0006142Malignant neoplasm of breast1CTD_human
TgeneALKC0007134Renal Cell Carcinoma1CTD_human
TgeneALKC0011570Mental Depression1PSYGENET
TgeneALKC0011581Depressive disorder1PSYGENET
TgeneALKC0027643Neoplasm Recurrence, Local1CTD_human
TgeneALKC0036341Schizophrenia1PSYGENET
TgeneALKC0079744Diffuse Large B-Cell Lymphoma1CTD_human
TgeneALKC0085269Plasma Cell Granuloma, Pulmonary1CTD_human
TgeneALKC0153633Malignant neoplasm of brain1CGI;CTD_human
TgeneALKC0278601Inflammatory Breast Carcinoma1CTD_human
TgeneALKC0279702Conventional (Clear Cell) Renal Cell Carcinoma1CTD_human
TgeneALKC0496899Benign neoplasm of brain, unspecified1CTD_human
TgeneALKC0678222Breast Carcinoma1CTD_human
TgeneALKC0750974Brain Tumor, Primary1CTD_human
TgeneALKC0750977Recurrent Brain Neoplasm1CTD_human
TgeneALKC0750979Primary malignant neoplasm of brain1CTD_human
TgeneALKC1257931Mammary Neoplasms, Human1CTD_human
TgeneALKC1266042Chromophobe Renal Cell Carcinoma1CTD_human
TgeneALKC1266043Sarcomatoid Renal Cell Carcinoma1CTD_human
TgeneALKC1266044Collecting Duct Carcinoma of the Kidney1CTD_human
TgeneALKC1306837Papillary Renal Cell Carcinoma1CTD_human
TgeneALKC1332079Anaplastic Large Cell Lymphoma, ALK-Positive1ORPHANET
TgeneALKC1458155Mammary Neoplasms1CTD_human
TgeneALKC1527390Neoplasms, Intracranial1CTD_human
TgeneALKC2931189Neural crest tumor1ORPHANET
TgeneALKC3899155hereditary neuroblastoma1GENOMICS_ENGLAND
TgeneALKC4704874Mammary Carcinoma, Human1CTD_human